The great revolution against Alzheimer’s: ‘It’s the first time in human history that we’ve managed to slow the disease’

New anti-amyloid drugs like lecanemab and donanemab are marking a "paradigm shift" in Alzheimer's treatment by demonstrating the ability to slow disease progression by 27-35%, according to a recent Lancet review. Despite controversies regarding their high cost (estimated $25,000 annually), potential side effects, and current applicability to only a limited subset of early-stage patients, experts argue their efficacy is comparable to other biologics. This development, alongside rapid advancements in diagnostic biomarkers and a pipeline of 138 additional drugs, signals significant future market growth and presents both opportunities and operational challenges for healthcare systems adapting to more intensive treatment protocols.

Analysis

The Alzheimer's therapeutic landscape is at a material inflection point, driven by the first generation of anti-amyloid drugs, lecanemab and donanemab, which have demonstrated the ability to slow disease progression by 27% and 35%, respectively. This breakthrough establishes a new, albeit controversial, standard of care for a condition affecting 50 million people globally. The long-term market potential is underscored by a robust pipeline of 138 drugs under investigation and a concurrent revolution in diagnostics, particularly the development of plasma-based biomarkers that could streamline patient identification and enable preventative screening. However, significant near-term headwinds exist. The drugs are accompanied by high costs, estimated at $25,000 per patient annually, and carry risks of serious side effects, including cerebral hemorrhages. Initial market penetration will be constrained, with estimates suggesting only 5% of Alzheimer's patients will be eligible. Furthermore, the intensive treatment protocol—requiring bi-weekly intravenous infusions and frequent MRI monitoring—poses a substantial logistical and financial burden on healthcare systems, a factor that, along with scientific skepticism from past failures, has contributed to a cautious regulatory environment, as seen with the European Medicines Agency (EMA).

Key Decisions for Investors

• Investors should recognize the long-term secular growth opportunity in the Alzheimer's therapeutic space, as the approval of the first disease-modifying drugs and a deep pipeline signal the beginning of a new, multi-billion dollar market.
• Monitor companies developing diagnostic biomarkers, especially non-invasive plasma-based tests, as their technology is a critical enabler for the commercial success of these therapies and will dictate the pace of market expansion.
• It is prudent to temper near-term revenue expectations for drug manufacturers due to significant adoption hurdles, including high costs, limited patient eligibility, and the substantial logistical strain on healthcare infrastructure, which will likely slow initial uptake.
• Closely track reimbursement decisions and real-world data on clinical efficacy versus adverse events, as this cost-benefit assessment by payers and clinicians will be the primary determinant of the commercial ramp for this new class of drugs.